126 related articles for article (PubMed ID: 28304377)
1. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity.
Lohberger B; Stuendl N; Leithner A; Rinner B; Sauer S; Kashofer K; Liegl-Atzwanger B
Sci Rep; 2017 Mar; 7():44700. PubMed ID: 28304377
[TBL] [Abstract][Full Text] [Related]
2. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity.
Lohberger B; Stuendl N; Wolf E; Liegl-Atzwanger B; Leithner A; Rinner B
BMC Cancer; 2013 Dec; 13():563. PubMed ID: 24289252
[TBL] [Abstract][Full Text] [Related]
3. The Biological Assessment of Shikonin and β,β-dimethylacrylshikonin Using a Cellular Myxofibrosarcoma Tumor Heterogeneity Model.
Lohberger B; Kaltenegger H; Eck N; Glänzer D; Leithner A; Kretschmer N
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958891
[TBL] [Abstract][Full Text] [Related]
4. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Sin Y; Ono T; Sugaya J; Iwata S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2021 Nov; 34(6):1911-1918. PubMed ID: 34383271
[TBL] [Abstract][Full Text] [Related]
6. Establishment and Characterization of NCC-MFS5-C1: A Novel Patient-Derived Cell Line of Myxofibrosarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Sugaya J; Kobayashi E; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Cells; 2022 Jan; 11(2):. PubMed ID: 35053323
[TBL] [Abstract][Full Text] [Related]
7. Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.
Heitzer E; Sunitsch S; Gilg MM; Lohberger B; Rinner B; Kashofer K; Stündl N; Ulz P; Szkandera J; Leithner A; Liegl-Atzwanger B
Mod Pathol; 2017 Dec; 30(12):1698-1709. PubMed ID: 28776571
[TBL] [Abstract][Full Text] [Related]
8. Metastatic heterogeneity in a spontaneously metastatic HSV-2 induced hamster fibrosarcoma: association of phenotypic and genotypic properties with metastatic potential.
Teale DM; Rees RC
Invasion Metastasis; 1987; 7(3):129-43. PubMed ID: 3036738
[TBL] [Abstract][Full Text] [Related]
9. A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models.
Guerrieri AN; Bellotti C; Penzo M; Columbaro M; Pannella M; De Vita A; Gambarotti M; Mercatali L; Laranga R; Dozza B; Vanni S; Corsini S; Frisoni T; Miserocchi G; Ibrahim T; Lucarelli E
BMC Cancer; 2023 Dec; 23(1):1194. PubMed ID: 38057796
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines.
Zhou QH; Deng CZ; Li ZS; Chen JP; Yao K; Huang KB; Liu TY; Liu ZW; Qin ZK; Zhou FJ; Huang W; Han H; Liu RY
Cell Death Dis; 2018 Jun; 9(6):684. PubMed ID: 29880898
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a novel myxofibrosarcoma cell line.
Kawashima H; Ogose A; Gu W; Nishio J; Kudo N; Kondo N; Hotta T; Umezu H; Tohyama T; Nishijima H; Iwasaki H; Endo N
Cancer Genet Cytogenet; 2005 Aug; 161(1):28-35. PubMed ID: 16080955
[TBL] [Abstract][Full Text] [Related]
13. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.
Mamlouk S; Childs LH; Aust D; Heim D; Melching F; Oliveira C; Wolf T; Durek P; Schumacher D; Bläker H; von Winterfeld M; Gastl B; Möhr K; Menne A; Zeugner S; Redmer T; Lenze D; Tierling S; Möbs M; Weichert W; Folprecht G; Blanc E; Beule D; Schäfer R; Morkel M; Klauschen F; Leser U; Sers C
Nat Commun; 2017 Jan; 8():14093. PubMed ID: 28120820
[TBL] [Abstract][Full Text] [Related]
14. Detection of GNAS mutations in intramuscular / cellular myxomas as diagnostic tool in the classification of myxoid soft tissue tumors.
Sunitsch S; Gilg MM; Kashofer K; Gollowitsch F; Leithner A; Liegl-Atzwanger B
Diagn Pathol; 2018 Aug; 13(1):52. PubMed ID: 30111377
[TBL] [Abstract][Full Text] [Related]
15. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
Li CF; Wang JM; Kang HY; Huang CK; Wang JW; Fang FM; Wang YH; Wu WR; Li SH; Yu SC; Lee JC; Lan J; Shiue YL; Wu LC; Huang HY
Clin Cancer Res; 2012 Mar; 18(6):1598-610. PubMed ID: 22322669
[TBL] [Abstract][Full Text] [Related]
16. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
17. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of a novel HPV-negative laryngeal squamous cell carcinoma cell line, FD-LSC-1, with missense and nonsense mutations of TP53 in the DNA-binding domain.
Wu CP; Zhou L; Gong HL; Du HD; Tian J; Sun S; Li JY
Cancer Lett; 2014 Jan; 342(1):92-103. PubMed ID: 24001612
[TBL] [Abstract][Full Text] [Related]
19. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma.
Mersch S; Riemer JC; Schlünder PM; Ghadimi MP; Ashmawy H; Möhlendick B; Topp SA; Arent T; Kröpil P; Stoecklein NH; Gabbert HE; Knoefel WT; Krieg A
Tumour Biol; 2016 Feb; 37(2):2341-51. PubMed ID: 26373732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
